Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab + cemdisiran versus C5 inhibitor control in treatment-naive or recently untreated PNH
2023-509657-31-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of pozelimab, cemdisiran, ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) (4 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Percent change in lactate dehydrogenase, Adequate control of hemolysis at each visit and 1 more. Planned start Dec 2024; status: authorised.
02
Drugs
pozelimabcemdisiranravulizumabeculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2023-509657-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509657-31-00.